Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 16/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.44 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2530398 | 0.91 | MTOR (0.51) | MTORPIK3CAPIK3CG | |
| SCHEMBL2528866 | 0.91 | PIK3CA (0.51) | MTORPIK3CAPIK3CG | |
| SCHEMBL12220646 | 0.89 | PIK3CA (0.54) | MTORPIK3CAPIK3R1PIK3CG | |
| SCHEMBL2535795 | 0.87 | MTOR (0.43) | MTORPIK3CAPIK3CG | |
| SCHEMBL2535269 | 0.86 | HDAC1 (0.46) | MTORPIK3CAPIK3R1PIK3CG | |
| SCHEMBL2532761 | 0.86 | PIK3CD (0.48) | — | |
| SCHEMBL2533264 | 0.84 | ALDH1A1 (0.44) | MTORKDM4EALDH1A1MAPK1 | |
| SCHEMBL2537650 | 0.83 | SMN1; SMN2 (0.42) | MTORKDM4EALDH1A1 | |
| SCHEMBL2531321 | 0.81 | PIK3CA (0.49) | MTORPIK3CAPIK3R1PIK3CG | |
| SCHEMBL2531267 | 0.81 | PIK3CA (0.54) | MTORKDM4EALDH1A1MAPK1TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110257170-A1 | 4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES | MERCK SERONO SA (CH) | 2011-10-20 | — | — | US | disclosed |
| US-20110257170-A1 | 4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES | MERCK SERONO SA (CH) | 2011-10-20 | — | — | US | disclosed |
| US-20110257170-A1 | 4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES | MERCK SERONO SA (CH) | 2011-10-20 | — | — | US | disclosed |
| WO-2010037765-A2 | 4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES | MERCK SERONO S.A. (CH) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257170-A1 | 4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES | PIK3CA, PIK3CD, PIK3CG | MTOR 42/4885KDM4E 609/4885ALDH1A1 2503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.